Tango Therapeutics (NASDAQ:TNGX – Get Free Report) announced its earnings results on Monday. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.02), Zacks reports. Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%.
Tango Therapeutics Stock Performance
Shares of TNGX opened at $1.12 on Monday. The firm has a market cap of $121.08 million, a PE ratio of -0.95 and a beta of 1.02. Tango Therapeutics has a 52-week low of $1.03 and a 52-week high of $12.02. The business’s 50 day moving average price is $1.51 and its two-hundred day moving average price is $2.66.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Tango Therapeutics in a research note on Monday, April 14th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $12.33.
Tango Therapeutics Company Profile
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
Read More
- Five stocks we like better than Tango Therapeutics
- Using the MarketBeat Stock Split Calculator
- Tech Bears Should Jump on These 3 Inverse ETFs
- Why is the Ex-Dividend Date Significant to Investors?
- 5 Reasons the Rebound in Microchip Technology Stock Is Real
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Rocket Lab: Earnings Miss But Neutron Momentum Holds
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
